Navigation Links
TAK-390MR Phase 3 data presented at Digestive Disease Week
Date:5/19/2008

SAN DIEGO, Calif. May 18, 2008 TAP Pharmaceutical Products Inc. today reported results from three pivotal Phase 3 studies evaluating investigational new drug TAK-390MR, the first proton pump inhibitor (PPI) with an innovative dual delayed release technology, in healing patients with erosive esophagitis (EE) and in maintenance of healed EE. The data were presented at the Digestive Disease Week (DDW) annual meeting in San Diego.

The innovative dual delayed release technology delivers TAK-390MR in two separate releases, which is a first in the PPI class and makes TAK-390MR a very interesting potential future treatment option, said Dr. David Peura, professor of medicine, University of Virginia Health System, past president of the American Gastroenterological Association.

Data from the two separate EE healing studies demonstrated that patients treated with TAK-390MR 60 mg and 90 mg experienced higher overall healing after eight weeks, versus patients taking lansoprazole 30 mg. In addition, data from a six-month maintenance of healed EE study demonstrated that patients treated with TAK-390MR 30 mg and 60 mg experienced statistically significant overall maintenance and symptom relief over placebo.

Healing of Erosive Esophagitis Studies

TAK-390MR was compared to lansoprazole in two identically designed, double-blind, randomized, controlled trials in patients with confirmed EE. A total of 4,092 patients were enrolled in the two global studies. The primary objective was to evaluate overall healing rates over eight weeks after once-daily administration of TAK-390MR 60 mg or 90 mg or lansoprazole 30 mg. The results for each study were analyzed using life table and crude rate methods.

Results from these trials demonstrated that TAK-390MR 60 mg and 90 mg produced consistently high healing rates for patients with EE. In one study, the life table analysis showed that 93 percent and 95 percent of TAK-390MR patients (60 mg a
'/>"/>

Contact: Kelly Thornicroft
kthronicroft@wcpglobal.com
773-405-4515
WeissComm Partners
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Ovation further advances development pipeline with new phase III epilepsy study
2. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
3. Mannatech Launches Phase One of New Sales and Training Tools
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Manic phase of bipolar disorder benefits from breast cancer medication
6. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
7. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
8. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... July 02, 2015 , ... ... M.D., to the orthopedic and spine surgery team at their Anaheim clinic. Dr. ... and tendonitis. Along with the spine and spine surgery, Dr. Krishnareddy also specializes ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... Real Time Pain Relief (RTPR), ... an agreement with Big Sky PBR to sponsor The Fifth Annual Big Sky ... Pain Relief will offer product samples of their popular pain relief lotion and products at ...
(Date:7/2/2015)... ... July 02, 2015 , ... Scientists ... received nearly $4 million through five federal grants to study a group of ... the deadly diseases. , The research will be conducted in the Regional ...
(Date:7/2/2015)... OR (PRWEB) , ... July 02, 2015 , ... Hand ... During the current summer flu season, according to fresh water advocate and radio host ... on the hands. Kleyne cautions that for maximum effectiveness, hand sanitizers must be applied ...
(Date:7/2/2015)... ... July 02, 2015 , ... After conducting a nationwide executive ... Medical Center in Yuma, Ariz., has hired Robert Trenschel, DO, as chief executive ... management, Dr. Trenschel will assume his new duties at Yuma Regional Medical Center on ...
Breaking Medicine News(10 mins):Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 2Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 3Health News:Real Time Pain Relief Sponsors The Fifth Annual Big Sky Professional Bull Riders Event at Big Sky Town Center in July 2Health News:Real Time Pain Relief Sponsors The Fifth Annual Big Sky Professional Bull Riders Event at Big Sky Town Center in July 3Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 2Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 3Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 4Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 2Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 3Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 2Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 3
... News) -- Among certain patients with a history of ... (dabigatran) appears to be as effective as the anticoagulant ... research reveals. Specifically, the new study suggests that ... as effectively as warfarin among those facing an elevated ...
... cancer patients are more likely to have joint pain from ... according to a study presented at the American College of ... is one of the first to identify factors that increase ... AI therapy. AIs, the standard adjuvant therapy for post-menopausal ...
... how an amphibious fish stays alive for up to two months ... small fishonly about an inch or two longthat live in temporary ... and Florida. During dry seasons when their pools disappear, the fish ... they stay moist, they can survive for extended periods out of ...
... Serena Gordon HealthDay Reporter , SUNDAY, Nov. 7 ... more than the joints, new research suggests. The ... buildup of plaque in the blood vessels, potentially increasing the ... The good news from the study is that certain drugs ...
... treating children with night-time cough and congestion and improves ... State College of Medicine researchers. , "Upper respiratory infections ... said Ian Paul, M.D., M.Sc., associate professor of pediatrics ... are disruptive for children, and often disturb sleep for ...
... HILL, N.C. In the largest study to date ... improvement in pain, fatigue, stiffness and sense of well-being. ... improved, said Leigh Callahan, PhD, the study,s lead author, ... Chapel Hill School of Medicine and a member of ...
Cached Medicine News:Health News:New Drug, Pradaxa, May Prevent Second Stroke in Certain Heart Patients 2Health News:New Drug, Pradaxa, May Prevent Second Stroke in Certain Heart Patients 3Health News:Study sheds light on aromatase inhibitor joint pain syndrome 2Health News:Study sheds light on aromatase inhibitor joint pain syndrome 3Health News:Special skin keeps fish species alive on land 2Health News:Rheumatoid Arthritis May Raise Risk of Blood Vessel Plaque 2Health News:Rheumatoid Arthritis May Raise Risk of Blood Vessel Plaque 3Health News:Vapor rub relieves cold symptoms for children, helps them sleep better 2Health News:Vapor rub relieves cold symptoms for children, helps them sleep better 3Health News:Study: Tai Chi relieves arthritis pain, improves reach, balance, well-being 2
(Date:7/2/2015)... FRANCISCO , July 2, 2015  The Green ... ), the world,s first HIPAA compliant mobile app that ... of farm-to-table fresh medical marijuana, announced today that their ... Unlike Eaze, Meadow and more than half a ... the last year, Loud Cannabis is unique in that ...
(Date:7/2/2015)... 2, 2015   Decision Resources Group ... identify less frequent dosing as the highest unmet ... the burden on both patients and providers associated ... (VEGF) injections, which are the current standard of ... which is in development for dosing every two ...
(Date:7/2/2015)... 2015 Research ... addition of the "2015 New Frontiers ... Emerging Technologies, Competitive Landscape" report to ... in Clinical Chemistry and Immunodiagnostics: Global Challenges, ... seven-country strategic analysis of major business opportunities ...
Breaking Medicine Technology:New Cannabis Delivery App Gets Product to Patient in Under 7 Minutes 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2
This flexiable metal clip-on easily attaches to most frames and allows for excellent radiation protection. Not available with side shields or in prescription....
... of extremely durable nylon that exhibits superior ... molded wrap around feature provides maximum comfort ... weight evenly over the nose while providing ... shields. Also available with adjustable nose ...
... optical steel base metal ... with custom fitted lead ... a seal to the ... scatter radiation protection. Includes ...
... steel base metal with bronze ... custom fitted 0.50mm leaded side ... to the front lenses for ... exposure. Includes adjustable non-slip silicon ...
Medicine Products: